Premium
Evaluation of the toxic effect of chemotherapeutic drugs: Study on the biodistribution of 99m Tc‐radiopharmaceuticals used in bone scintigraphy in mice
Author(s) -
Gomes M. L.,
Mattos D. M. M.,
Freitas R. S.,
Moreno S. R. F.,
BernardoFilho M.
Publication year - 2001
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.25804401219
Subject(s) - biodistribution , kidney , spleen , technetium 99m , chemistry , stomach , pharmacology , vincristine , ovary , bone marrow , scintigraphy , nuclear medicine , medicine , pathology , chemotherapy , in vitro , cyclophosphamide , biochemistry
It is accepted that a variety of factors can alter the biodistribuition of radiopharmaceuticals and one such factor is the drug therapy. Since patients on chemotherapeutic treatment can be submitted to a nuclear medicine procedure, we studied in mice, the effect of chemotherapeutic drugs on the biodistribution of the technetium‐99m‐radiopharmaceuticals. Mitomycin‐C or vincristine were administered in mice (n=15) during some days. After tbat, the methylenediphosphonic acid labelled with technetium‐99m ( 99m Tc‐MDP) was also injected and the animals were sacrified. The organs were isolated and counted in a well counter. The percentages of radioactivity (%ATI) in the organs were calculated. Concerning to mitomycin‐C, the results have shown that the %ATI has increased in pancreas, ovary, uterus, stomach, kidney, spleen, thymus, heart, lung, liver and bone. Concerning to vincristine, the results have shown that the %ATI has decreased in uterus, ovary, spleen, thymus, kidney, liver, stomach, heart and brain. In general, the alterations in the uptake of the radiopharmaceutical could be justified by the metabolic process, the therapeutic effect and/or the toxic action of mitomycin‐C and vincristine in specific organs. The effect of these chemotherapeutic drugs on the biodistribution of other 99m Tc‐radiopharmaceuticals are now in progress.